STIM
Neuronetics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$2.90
−2.36%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$3.01
From 52W high−12.12%
Volume1.11M
Market cap$220.97M
P/E (TTM)—
P/S (TTM)1.4x
Div yield—
Key dataSep 18, 2026
Open
$3.01
From 52W high
−12.12%
Volume
1.11M
Market cap
$220.97M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−13.7x
P/E (TTM)
—
RSI (14)
54.2
MomentumView details →
1D Return
−2.36%
YTD Return
+110.87%
SummaryUpdated Jun 1, 2026
Neuronetics, Inc. (NASDAQ:STIM) is a commercial-stage medical technology company founded in 2001 and headquartered in Malvern, Pennsylvania. The company went public in June 2018 and has evolved from a pure medical device manufacturer into a vertically integrated mental health care provider through its 2024 acquisition of Greenbrook TMS. Neuronetics specializes in non-invasive brain stimulation therapies for treating various neurohealth disorders, with a primary focus on depression treatment through its flagship NeuroStar Advanced Therapy System.
Similar companies
Latest newsMore news →
Neuronetics announced the integration of its TrakStar practice management platform with AdvancedMD, marking the first-ever TMS integration with an EHR/EMR system.12d agoNir Naor was appointed Executive Vice President, Chief Financial Officer, and Treasurer of Neuronetics, Inc., effective July 23, 2026, and subsequently became principal financial and accounting officer on August 12, 2026, succeeding Francis X. Brown III as interim principal financial and accounting officer.35d ago